IBDEI0G9 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7537,2)
 ;;=^269598
 ;;^UTILITY(U,$J,358.3,7538,0)
 ;;=402.11^^35^472^32
 ;;^UTILITY(U,$J,358.3,7538,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7538,1,4,0)
 ;;=4^402.11
 ;;^UTILITY(U,$J,358.3,7538,1,5,0)
 ;;=5^HTN with CHF
 ;;^UTILITY(U,$J,358.3,7538,2)
 ;;=HTN with CHF^269599
 ;;^UTILITY(U,$J,358.3,7539,0)
 ;;=403.11^^35^472^37
 ;;^UTILITY(U,$J,358.3,7539,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7539,1,4,0)
 ;;=4^403.11
 ;;^UTILITY(U,$J,358.3,7539,1,5,0)
 ;;=5^HTN with Renal Failure
 ;;^UTILITY(U,$J,358.3,7539,2)
 ;;=^269608
 ;;^UTILITY(U,$J,358.3,7540,0)
 ;;=404.10^^35^472^35
 ;;^UTILITY(U,$J,358.3,7540,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7540,1,4,0)
 ;;=4^404.10
 ;;^UTILITY(U,$J,358.3,7540,1,5,0)
 ;;=5^HTN with Heart & Renal Involvement
 ;;^UTILITY(U,$J,358.3,7540,2)
 ;;=^269618
 ;;^UTILITY(U,$J,358.3,7541,0)
 ;;=404.11^^35^472^33
 ;;^UTILITY(U,$J,358.3,7541,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7541,1,4,0)
 ;;=4^404.11
 ;;^UTILITY(U,$J,358.3,7541,1,5,0)
 ;;=5^HTN with CHF & Renal Involvement
 ;;^UTILITY(U,$J,358.3,7541,2)
 ;;=^269619
 ;;^UTILITY(U,$J,358.3,7542,0)
 ;;=404.12^^35^472^36
 ;;^UTILITY(U,$J,358.3,7542,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7542,1,4,0)
 ;;=4^404.12
 ;;^UTILITY(U,$J,358.3,7542,1,5,0)
 ;;=5^HTN with Heart Involvement & Renal Failure
 ;;^UTILITY(U,$J,358.3,7542,2)
 ;;=^269620
 ;;^UTILITY(U,$J,358.3,7543,0)
 ;;=404.13^^35^472^34
 ;;^UTILITY(U,$J,358.3,7543,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7543,1,4,0)
 ;;=4^404.13
 ;;^UTILITY(U,$J,358.3,7543,1,5,0)
 ;;=5^HTN with CHF & Renal failure
 ;;^UTILITY(U,$J,358.3,7543,2)
 ;;=^269621
 ;;^UTILITY(U,$J,358.3,7544,0)
 ;;=401.9^^35^472^57
 ;;^UTILITY(U,$J,358.3,7544,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7544,1,4,0)
 ;;=4^401.9
 ;;^UTILITY(U,$J,358.3,7544,1,5,0)
 ;;=5^Hypertension, Essential
 ;;^UTILITY(U,$J,358.3,7544,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,7545,0)
 ;;=272.0^^35^472^55
 ;;^UTILITY(U,$J,358.3,7545,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7545,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,7545,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,7545,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,7546,0)
 ;;=272.1^^35^472^58
 ;;^UTILITY(U,$J,358.3,7546,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7546,1,4,0)
 ;;=4^272.1
 ;;^UTILITY(U,$J,358.3,7546,1,5,0)
 ;;=5^Hypertriglyceridemia
 ;;^UTILITY(U,$J,358.3,7546,2)
 ;;=Hypertriglyceridemia^101303
 ;;^UTILITY(U,$J,358.3,7547,0)
 ;;=272.2^^35^472^63
 ;;^UTILITY(U,$J,358.3,7547,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7547,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,7547,1,5,0)
 ;;=5^Mixed Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,7547,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,7548,0)
 ;;=396.0^^35^472^11
 ;;^UTILITY(U,$J,358.3,7548,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7548,1,4,0)
 ;;=4^396.0
 ;;^UTILITY(U,$J,358.3,7548,1,5,0)
 ;;=5^Aortic and Mitral Stenosis
 ;;^UTILITY(U,$J,358.3,7548,2)
 ;;=Aortic and Mitral Stenosis^269580
 ;;^UTILITY(U,$J,358.3,7549,0)
 ;;=414.02^^35^472^18
 ;;^UTILITY(U,$J,358.3,7549,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7549,1,4,0)
 ;;=4^414.02
 ;;^UTILITY(U,$J,358.3,7549,1,5,0)
 ;;=5^CAD, Occlusion of Venous Graft
 ;;^UTILITY(U,$J,358.3,7549,2)
 ;;=CAD, Occlusion of Venous Graft^303282
 ;;^UTILITY(U,$J,358.3,7550,0)
 ;;=459.10^^35^472^73
 ;;^UTILITY(U,$J,358.3,7550,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7550,1,4,0)
 ;;=4^459.10
 ;;^UTILITY(U,$J,358.3,7550,1,5,0)
 ;;=5^Post Phlebotic Syndrome
 ;;^UTILITY(U,$J,358.3,7550,2)
 ;;=Post Phlebotic Syndrome^328597
 ;;^UTILITY(U,$J,358.3,7551,0)
 ;;=428.20^^35^472^50
 ;;
 ;;$END ROU IBDEI0G9
